93 related articles for article (PubMed ID: 10319748)
61. Profile of nimotuzumab in the treatment of high-grade glioma.
Yang QY; Guo CC; Chen ZP
Onco Targets Ther; 2015; 8():819-25. PubMed ID: 25926743
[TBL] [Abstract][Full Text] [Related]
62. Interrogating tumor metabolism and tumor microenvironments using molecular positron emission tomography imaging. Theranostic approaches to improve therapeutics.
Jacobson O; Chen X
Pharmacol Rev; 2013; 65(4):1214-56. PubMed ID: 24064460
[TBL] [Abstract][Full Text] [Related]
63. Treatment of children with high grade glioma with nimotuzumab: a 5-year institutional experience.
Cabanas R; Saurez G; Rios M; Alert J; Reyes A; Valdes J; Gonzalez MC; Pedrayes JL; Avila M; Herrera R; Infante M; Echevarria E; Moreno M; Luaces PL; Ramos TC
MAbs; 2013; 5(2):202-7. PubMed ID: 23575267
[TBL] [Abstract][Full Text] [Related]
64. Nimotuzumab prolongs survival in patients with malignant gliomas: A phase I/II clinical study of concomitant radiochemotherapy with or without nimotuzumab.
Hong J; Peng Y; Liao Y; Jiang W; Wei R; Huo L; Han Z; Duan C; Zhong M
Exp Ther Med; 2012 Jul; 4(1):151-157. PubMed ID: 23060940
[TBL] [Abstract][Full Text] [Related]
65. Protein-based tumor molecular imaging probes.
Lin X; Xie J; Chen X
Amino Acids; 2011 Nov; 41(5):1013-36. PubMed ID: 20232092
[TBL] [Abstract][Full Text] [Related]
66. Single chain epidermal growth factor receptor antibody conjugated nanoparticles for in vivo tumor targeting and imaging.
Yang L; Mao H; Wang YA; Cao Z; Peng X; Wang X; Duan H; Ni C; Yuan Q; Adams G; Smith MQ; Wood WC; Gao X; Nie S
Small; 2009 Feb; 5(2):235-43. PubMed ID: 19089838
[TBL] [Abstract][Full Text] [Related]
67. Targeted molecular imaging in oncology: focus on radiation therapy.
Nimmagadda S; Ford EC; Wong JW; Pomper MG
Semin Radiat Oncol; 2008 Apr; 18(2):136-48. PubMed ID: 18314068
[TBL] [Abstract][Full Text] [Related]
68. Multimodality imaging of the HER-kinase axis in cancer.
Cai W; Niu G; Chen X
Eur J Nucl Med Mol Imaging; 2008 Jan; 35(1):186-208. PubMed ID: 17846765
[TBL] [Abstract][Full Text] [Related]
69. Positron emission tomography (PET): expanding the horizons of oncology drug development.
Hammond LA; Denis L; Salman U; Jerabek P; Thomas CR; Kuhn JG
Invest New Drugs; 2003 Aug; 21(3):309-40. PubMed ID: 14578681
[TBL] [Abstract][Full Text] [Related]
70. Evaluation of systemically administered radiolabeled epidermal growth factor as a brain tumor targeting agent.
Yang W; Barth RF; Leveille R; Adams DM; Ciesielski M; Fenstermaker RA; Capala J
J Neurooncol; 2001 Oct; 55(1):19-28. PubMed ID: 11804279
[TBL] [Abstract][Full Text] [Related]
71. 99mTc-labeled antihuman epidermal growth factor receptor antibody in patients with tumors of epithelial origin: Part III. Clinical trials safety and diagnostic efficacy.
Ramos-Suzarte M; Rodríguez N; Oliva JP; Iznaga-Escobar N; Perera A; Morales A; Gonzalez N; Cordero M; Torres L; Pimentel G; Borrón M; González J; Torres O; Rodríguez T; Pérez R
J Nucl Med; 1999 May; 40(5):768-75. PubMed ID: 10319748
[TBL] [Abstract][Full Text] [Related]
72. Technetium-99m-antiepidermal growth factor-receptor antibody in patients with tumors of epithelial origin: part II. Pharmacokinetics and clearances.
Iznaga-Escobar N; Torres Arocha LA; Morales Morales A; Ramos Suzarte M; Rodríguez Mesa N; Pérez Rodríguez R
J Nucl Med; 1998 Nov; 39(11):1918-27. PubMed ID: 9829584
[TBL] [Abstract][Full Text] [Related]
73. Technetium-99m-labeled anti-EGF-receptor antibody in patients with tumor of epithelial origin: I. Biodistribution and dosimetry for radioimmunotherapy.
Iznaga-Escobar N; Torres LA; Morales A; Ramos M; Alvarez I; Pérez N; Fraxedas R; Rodríguez O; Rodríguez N; Pérez R; Lage A; Stabin MG
J Nucl Med; 1998 Jan; 39(1):15-23. PubMed ID: 9443731
[TBL] [Abstract][Full Text] [Related]
74. Phase I clinical evaluation of a neutralizing monoclonal antibody against epidermal growth factor receptor.
Crombet T; Torres O; Neninger E; Catalá M; Rodríguez N; Ramos M; Fernández E; Iznaga N; Pérez R; Lage A
Cancer Biother Radiopharm; 2001 Feb; 16(1):93-102. PubMed ID: 11279803
[TBL] [Abstract][Full Text] [Related]
75.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
76.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
77.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
78.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
79.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
80.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
